Argatroban in the management of heparin-induced thrombocytopenia

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 813-819

  Babuin, Luciano ^a   Pengo, Vittorio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Argatroban; Thrombocytopenia; Thrombosis

Indexed keywords

ARGATROBAN; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; WARFARIN; ANTITHROMBIN; PIPECOLIC ACID DERIVATIVE;

AMPUTATION; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARIN INDUCED THROMBOCYTOPENIA AND THROMBOSIS SYNDROME; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORTALITY; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PATIENT SATISFACTION; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; THROMBOSIS; ADULT; CHEMICALLY INDUCED DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTITHROMBINS; HEPARIN; HUMANS; PIPECOLIC ACIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOCYTOPENIA;

EID: 79952062775     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S3904     Document Type: Review

References (21)

1. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation. 2004;110:e454-e458.
2. Baroletti SA, Goldhaber SZ. Heparin-induced thrombocytopenia. Circulation. 2006;114:e355-e356.
3. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation. 2005;111: 2671-2683.
4. th editor). Chest. 2008;133:340S-380S.
5. Glaxo Smith Kline (Argatroban injection) [US prescribing information]. 2009. Available from: http://www.us.gsk.com/products/assets/us_argatroban.pdf
6. Koster A, Buz S, Hetzer R, Kuppe H, Breddin K, Harder S. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg. 2006;132:699-700.
7. Koster A, Hentschel T, Groman T, et al. Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. J Thorac Cardiovasc Surg. 2007;133:1376-1377.
8. Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy. 2004;24:409-414.
9. Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother. 2005;39:1601-1605.
10. Beiderlinden M, Treschan TA, Gorlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother. 2007;41: 749-754.
11. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother. 2003;37:652-654.
12. de Denus S, Spinler SA. Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann Pharmacother. 2003;37:1237-1240.
13. Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother. 2004;38:25-29.
14. Kodityal S, Nguyen PH, Kodityal A, Sherer J, Hursting MJ, Rice L. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med. 2006;21:86-92.
15. Smythe MA, Stephens JL, Koerber JM, Mattson JC. A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005;11:371-374.
16. Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy. 2005;25: 1736-1745.
17. Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging. 2007;24:489-499.
18. Rice L, Hursting MJ, Baillie GM, McCollum DA. Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. J Clin Pharmacol. 2007;47:1028-1034.
19. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843.
20. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849-1856.
21. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57:177-184.